Comparative clinical and economic analysis Jodantipyrin for emergency prevention of tick-borne encephalitis

Abstract

Objective: To conduct a comparative pharmacoeconomic analysis Jodantipyrin drugs and Human immunoglobulin against tick-borne encephalitis (TBE) for emergency prevention of tick-borne encephalitis in a health care system of the Russian Federation. Methodology: The study is an analysis of costs, cost-effectiveness and budget impact and consists of a single line of therapy. Results: Cost analysis shows that in the case of the health budget Jodantipyrin costs associated with treatment of established TBE 2.2 times lower than that of the Immunoglobulin against tick-borne encephalitis, and the costs of the use of means of emergency prevention Jodantipyrin - at 11,3 times less.

Keywords

• клещевой энцефалит
• фармакоэкономика
• анализ эффективности затрат
• анализ влияния на бюджет
• экстренная профилактика
• йодантипирин
• иммуноглобулин человека против клещевого энцефалита
• tick-borne encephalitis
• pharmacoeconomics
• cost-effectiveness analysis
• budget impact analysis
• emergency prevention
• jodantipyrin
• human immunoglobulin against tick-borne encephalitis